MX2011012015A - Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. - Google Patents
Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.Info
- Publication number
- MX2011012015A MX2011012015A MX2011012015A MX2011012015A MX2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A
- Authority
- MX
- Mexico
- Prior art keywords
- mci
- alzheimer
- disease
- treatment
- nifedipine
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- -1 nitroso nifedipine derivatives Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940034208 thyroxine Drugs 0.000 abstract 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21645209P | 2009-05-15 | 2009-05-15 | |
| US23455109P | 2009-08-17 | 2009-08-17 | |
| PCT/US2010/034721 WO2010132671A1 (en) | 2009-05-15 | 2010-05-13 | Treatment of mci and alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012015A true MX2011012015A (es) | 2012-04-30 |
Family
ID=43069025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012015A MX2011012015A (es) | 2009-05-15 | 2010-05-13 | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100292281A1 (enExample) |
| EP (1) | EP2429992A4 (enExample) |
| JP (1) | JP2012526844A (enExample) |
| AU (1) | AU2010249015A1 (enExample) |
| CA (1) | CA2761298A1 (enExample) |
| MX (1) | MX2011012015A (enExample) |
| WO (1) | WO2010132671A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067008B2 (en) | 2004-08-23 | 2011-11-29 | Yeda Research And Development Co. | Peptide inhibitors for mediating stress responses |
| CA2623638A1 (en) | 2005-09-30 | 2007-04-12 | Vitae Pharmaceuticals, Inc. | Treatment of cancer with specific rxr agonists |
| WO2012160563A2 (en) * | 2011-05-23 | 2012-11-29 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| EP2742155B1 (en) * | 2011-08-08 | 2018-01-24 | Advanced Genomic Technology LLC | Biomarker for alzheimer's disease and/or mild cognitively impairment |
| AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| SG11201408323RA (en) | 2012-06-15 | 2015-01-29 | Found Biomedical Res & Innov | Prophylactic and/or therapeutic agent for mild cognitive impairment |
| US8901305B2 (en) * | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| KR102489706B1 (ko) | 2015-10-31 | 2023-01-17 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| EP3426303B1 (en) | 2016-03-10 | 2022-06-15 | IO Therapeutics, Inc. | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| MX386643B (es) | 2016-03-10 | 2025-03-19 | Io Therapeutics Inc | Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas. |
| US11517549B2 (en) * | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| KR20240119103A (ko) | 2021-12-07 | 2024-08-06 | 아이오 테라퓨틱스, 인크. | Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2126533A1 (de) * | 1971-05-28 | 1972-12-14 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur Herstellung pharma zeutischer Zubereitungen |
| DE4342196A1 (de) * | 1993-12-10 | 1995-06-14 | Bayer Ag | Neue 4-Phenyl-substituierte 1,4-Dihydropyridine |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6066642A (en) * | 1996-01-29 | 2000-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
| WO1999043307A1 (en) * | 1998-02-26 | 1999-09-02 | Prange Arthur J Jr | Thyroid hormone replacement using sustained release triiodothyronine |
| EP1069918A4 (en) * | 1998-04-08 | 2002-02-20 | Univ Oregon Health Sciences | ACTIVATION OF GALLIUM CELL FIXATION |
| ES2334029T3 (es) * | 2003-05-15 | 2010-03-04 | Roskamp Research Llc | Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis. |
| JP2007512339A (ja) * | 2003-11-21 | 2007-05-17 | メモリー・ファーマシューティカルズ・コーポレイション | 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用 |
| JP5113523B2 (ja) * | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド |
| PT1874311E (pt) * | 2005-04-15 | 2011-11-25 | Res & Innovation S P A | Método para prevenir, retardar ou reverter a deposição anómala de amilóide |
| EP1877067A1 (en) * | 2005-04-26 | 2008-01-16 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| JP2007091664A (ja) * | 2005-09-29 | 2007-04-12 | Univ Of Tokushima | 細胞膜保護剤 |
| US20090286879A1 (en) * | 2005-12-02 | 2009-11-19 | Kiyoshi Hashizume | Preventive or Therapeutic Drug for Alzheimer-Type Dementia |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| JP2009073759A (ja) * | 2007-09-20 | 2009-04-09 | Univ Of Tokushima | Ｉｃａｍ−１発現抑制剤 |
-
2010
- 2010-05-13 AU AU2010249015A patent/AU2010249015A1/en not_active Abandoned
- 2010-05-13 WO PCT/US2010/034721 patent/WO2010132671A1/en not_active Ceased
- 2010-05-13 EP EP10775535A patent/EP2429992A4/en not_active Withdrawn
- 2010-05-13 CA CA2761298A patent/CA2761298A1/en not_active Abandoned
- 2010-05-13 US US12/779,345 patent/US20100292281A1/en not_active Abandoned
- 2010-05-13 MX MX2011012015A patent/MX2011012015A/es not_active Application Discontinuation
- 2010-05-13 JP JP2012511013A patent/JP2012526844A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012526844A (ja) | 2012-11-01 |
| EP2429992A4 (en) | 2012-11-28 |
| EP2429992A1 (en) | 2012-03-21 |
| AU2010249015A1 (en) | 2011-11-24 |
| CA2761298A1 (en) | 2010-11-18 |
| WO2010132671A1 (en) | 2010-11-18 |
| US20100292281A1 (en) | 2010-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| MY177001A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| TW200637522A (en) | Skin treatment articles and methods | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| MY173616A (en) | Compositions and methods for lowering triglycerides | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| SG10201407403UA (en) | Treatments For Gastrointestinal Disorders | |
| WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
| MY147247A (en) | Organic compounds and their uses | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
| EA200701995A1 (ru) | Способы уменьшения кальцификации | |
| TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
| NZ606276A (en) | Fastening Means | |
| UA85471C2 (ru) | Применение оксикодона для лечения висцеральной боли | |
| TW200716088A (en) | Formulations and methods for treating amyloidosis | |
| UA92593C2 (ru) | Лечение мастита энрофлоксацином | |
| ZA200708372B (en) | KIM-1 antibodies for treatment of Th2-mediated conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |